Latest Articles
March 1, 2026 Special Days and Important Dates: Endometriosis Awareness Day, Zero Discrimination Day – Full List of National and International Events - Bombay Times
March 1, 2026 Special Days and Important Dates: Endometriosis Awareness Day, Zero Discrimination Day – Full List of National and International Events Bombay Times
Published: Feb. 28, 2026, 11:30 a.m.
We have endometriosis: Here’s what we wish more people knew about the condition - The Portugal News
We have endometriosis: Here’s what we wish more people knew about the condition The Portugal News
Published: Feb. 28, 2026, 11:10 a.m.
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon - TipRanks
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon TipRanks
Published: Feb. 27, 2026, 7:47 p.m.
'Years being dismissed': Endometriosis patient campaigns for Jess's rule in Wales - ITVX
'Years being dismissed': Endometriosis patient campaigns for Jess's rule in Wales ITVX
Published: Feb. 27, 2026, 6:51 p.m.
How Endometriosis Patients Can Change The World: Cat Bohannon On Healt - Endometriosis Foundation of America
How Endometriosis Patients Can Change The World: Cat Bohannon On Healt Endometriosis Foundation of America
Published: Feb. 27, 2026, 4:54 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer MarketBeat
Published: Feb. 27, 2026, 4:50 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Yahoo Finance
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Yahoo Finance
Published: Feb. 27, 2026, 4:47 p.m.
ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval - TradingView
ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval TradingView
Published: Feb. 27, 2026, 3:34 p.m.
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data TipRanks
Published: Feb. 27, 2026, 3:24 p.m.
Advancing support for endometriosis and menstrual wellbeing - GOV.UK
Advancing support for endometriosis and menstrual wellbeing GOV.UK
Published: Feb. 27, 2026, 3:11 p.m.
Link copied to clipboard!